Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04095377
Other study ID # 0292-18
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 24, 2019
Est. completion date February 14, 2022

Study information

Verified date March 2019
Source QuantalX Neuroscience
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

DELPhI software developed for the analysis of EEG recordings in response to magnetic stimulation in relation to clinical data.


Description:

Collection of EEG data, recorded at Sagol center for hyperbaric medicine and research in the years of 2017-2019 of patients arriving to be treated at the hyperbaric chamber before,during and after treatments. EEG was recorded of patients during cognitive tests, resting state and during magnetic stimulation as a part of other array of tests performed at the Sagol center. Anonymous EEG data along with MRI scans, PET-CT, SPECT, cognitive tests, Medical history and medications will be transferred to QuantalX Neuroscience LTD. QuantalX Neuroscience is intending to use the above mentioned data in order to improve DELPhI, an algorithm for the analysis of EEG recordings in response to magnetic stimulation.


Recruitment information / eligibility

Status Completed
Enrollment 875
Est. completion date February 14, 2022
Est. primary completion date February 14, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects over the age of 18. - Subjects that performed at least one EEG test as a part of their hyperbaric treatment at Sagol center Asaf-Harophe. Exclusion Criteria: - Subjects with no EEG test or that their EEG recording is in pure quality, not allowing analysis of the data.

Study Design


Intervention

Other:
No intervention, this is a retrospective study.
No intervention, this is a retrospective study.

Locations

Country Name City State
Israel Asaf-Harophe Rishon LeZion

Sponsors (1)

Lead Sponsor Collaborator
QuantalX Neuroscience

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Defining Plasticity (the ratio between excitatory to inhibitory brain response) Means and STD in each cohort. Measure of the mean and STD Plasticity of each cohort. through study completion, an average of 1 year
Primary Defining Connectivity (dispersion of brain signal) Means and STD in each cohort. Measure of the mean and STD Connectivity of each cohort. through study completion, an average of 1 year
Primary Defining Plasticity (the ratio between excitatory to inhibitory brain response) standard error (SEM) in each cohort. Measure of the standard error (SEM) of Plasticity of each cohort. through study completion, an average of 1 year
Primary Defining Connectivity (dispersion of brain signal) standard error (SEM) in each cohort. Measure of the standard error (SEM) of Connectivity of each cohort. through study completion, an average of 1 year
Primary Defining Plasticity (excitation/inhibition brain response) coefficient of variation (CV%) in each cohort. Measure of the coefficient of variation (CV%) of Plasticity of each cohort. through study completion, an average of 1 year
Primary Defining Connectivity (dispersion of brain signal) coefficient of variation (CV%) in each cohort. Measure of the coefficient of variation (CV%) of Connectivity of each cohort. through study completion, an average of 1 year
Primary Defining Plasticity (excitation/inhibition brain response) minimum, median, maximum in each cohort. Measure of the minimum, median, maximum of Plasticity of each cohort. through study completion, an average of 1 year
Primary Defining Connectivity (dispersion of brain signal) minimum, median, maximum in each cohort. Measure of the minimum, median, maximum of Connectivity of each cohort. through study completion, an average of 1 year
Primary Defining Plasticity (excitation/inhibition brain response) 95% confidence interval in each cohort. Measure of the 95% confidence interval of Plasticity of each cohort. through study completion, an average of 1 year
Primary Defining Connectivity (dispersion of brain signal) 95% confidence interval in each cohort. Measure of the 95% confidence interval of Connectivity of each cohort. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1